

(12) PATENT APPLICATION PUBLICATION

(19) INDIA

(22) Date of filing of Application :31/12/2024

(21) Application No.202411105147 A

(43) Publication Date : 10/01/2025

(54) Title of the invention : SURAMIN-BASED THERAPEUTIC FORMULATION FOR NEUROINFLAMMATION AND SYNAPTIC DYSFUNCTION

(51) International classification

(86) International Application No

(87) International Publication No

(61) Patent of Addition to Application Number

(62) Divisional to Application Number

:A61K0009000000, A61P0025000000, A61K0045060000, A61P0025280000, A61K0031185000

:NA

:NA

:NA

:NA

:NA

:NA

(71)Name of Applicant :

1)Chitkara University

Address of Applicant :Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura -----

2)Chitkara Innovation Incubator Foundation

Name of Applicant : NA

Address of Applicant : NA

(72)Name of Inventor :

1)Dr. Amarjot Kaur

Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura -----

2)Ojashvi Sharma

Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura -----

3)Amit Kumar

Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura -----

4)Pragati Silakari

Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura -----

5)Thakur Gurjeet Singh

Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura -----

(57) Abstract :

The invention relates to a method and therapeutic formulation for treating stress-induced neurobehavioral disorders using Suramin. The therapeutic formulation is designed as a sublingual film that includes Suramin, a water-soluble polymer, a plasticizer, and pharmaceutically acceptable excipients. This formulation aims to address chronic stress-induced neuroinflammation and synaptic dysfunction, leading to improved neurobehavioral outcomes, reduced neuroinflammation, enhanced synaptic integrity, and better mood and cognitive functions. The method provides a disease-modifying effect by targeting both inflammation and synaptic health, offering a novel therapeutic avenue compared to conventional therapies. Reference Fig 1

No. of Pages : 14 No. of Claims : 10